BioCentury
ARTICLE | Company News

Incyte 'downsizing' IDO1 program, ends some combo trials

May 1, 2018 8:55 PM UTC

Incyte Corp. (NASDAQ:INCY) reported 1Q18 earnings and said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination with anti-PD-1 mAbs Keytruda pembrolizumab from Merck & Co. Inc (NYSE:MRK) or Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY).

The discontinued trials include four evaluating epacadostat plus Keytruda in squamous cell carcinoma of the head and neck (SCCHN), kidney cancer and bladder cancer, plus two evaluating epacadostat plus Opdivo in non-small cell lung cancer (NSCLC) and SCCHN...